


# CRRT in the ICU : Initiating and Optimizing Therapy


R.T. Noel Gibney MB FRCP(C) FRCPI

*Division of Critical Care Medicine, University of Alberta, Edmonton, Alberta, CANADA*



## Seminar overview

- **Part 1**
  - Treatment selection, access and dose
  - Case study
- **Part 2**
  - Fluid balance and electrolyte management
  - Case study
- **Part 3**
  - Monitoring and modification of anticoagulation
  - Case study
- **Discussion**



## Purpura Fulminans

- 12:05 hrs 18 y/o male presented to UAH ER.
- Called on phone for help. Found collapsed on floor in apartment. Incontinent of diarrhoea. Rousable but confused. HR 130, BP 85 systolic. ? Petechial rash. IV commenced and NS started.
- Previously healthy
- Member of college drama group
- On arrival in ER HR 140, BP 90/40, T 39 C, neck supple, evolving generalized purpuric rash.



- Rapid deterioration in hemodynamic, respiratory and acid base status.
- WBC 2.3 with 55% band forms, Plts 78, INR 2.1, PTT 67
- Urea 13 mmol/l, Creatinine 142µmol/l
- Cefotaxime 2 gms IV q 8H
- PA catheter inserted
  - PCWP 10
  - CI 3.5,
  - SVRI 900
- Aggressive fluid resuscitation guided by PA cath
- Progressive hypoxemia and fatigue
- 19:00 hrs: Intubated and placed on mechanical ventilation

- Noradrenaline infusion for BP support but required addition of adrenaline due to progressive decrease in CI to 2.4
- Vasopressin infusion 0.03 u/min
- Hydrocortisone 100 mg IV and 50 mg IV q 8H
- Progressive increase in noradrenaline infusion dose to maintain SBP>90
- Progressive increase in serum lactate to 10 nmol/l
- Progressive peripheral digital cyanosis

- Progressive coagulopathy, INR 1.9, PTT 95, Plts 41
- Progressive hypoxaemia (P/F ratio 110) and development of pulm infiltrates
- Ventilated with lung protective strategy
  - PEEP 15 cm H<sub>2</sub>O, Vt 420 ml (6 ml/kg),
- 24:00 hrs: FIO<sub>2</sub> 0.8, pH 7.18, Noradrenaline 20 mcg/min, Adrenaline 25 mcg/min, CI 3.1, SVRI 825
- Issues?
- Strategies?

### **Problems**

- Meningococemia
- Septic shock
- Purpura fulminans
- Coagulopathy
- Metabolic acidosis
  - Anion gap
  - Lactic acidosis
- ARDS
- Acute renal failure
- Peripheral digital ischemia

### **Acute renal failure**

- RRT?

### **Acute renal failure**

- RRT?
  - Yes
    - Anuria
    - Metabolic acidosis
    - Fluid management

### **Acute renal failure**

- RRT?
  - Yes
    - Anuria
    - Metabolic acidosis
    - Fluid management
- IHD or CRRT?


### **Acute renal failure**

- RRT?
  - Yes
    - Anuria
    - Metabolic acidosis
    - Fluid management
- IHD or CRRT?
  - CRRT
    - Hemodynamic instability
    - Vasopressor dependency

### **Acute renal failure**

- RRT?
  - Yes
    - Anuria
    - Metabolic acidosis
    - Fluid management
- IHD or CRRT?
  - CRRT
    - Hemodynamic instability
    - Vasopressor dependency
- Mode?

### **Solute clearance**




### **Mechanisms of Solute Removal**

- Diffusion
- Ultrafiltration
- Diffusion + Ultrafiltration
- Adsorption


### **Principles of Haemodialysis**

- Solute clearance by diffusion
- Suitable for removal of small molecules, and most middle molecules

### **Diffusive solute clearance**




### **Diffusive solute clearance**




### **CVVHD**

- Fluid removal
- Solute removal (small molecules)
- Counter-current dialysis flow
- Diffusion
- Back filtration




### **Principles of Haemofiltration**

### **Ultrafiltration**




The transfer of solute in a stream of solvent, across a semipermeable membrane, mediated by a hydrostatic force


### **Convective solute clearance**



### Convective solute clearance




### Convective solute removal



Coffee maker analogy of haemofiltration  
Removal of large volumes of solute and fluid via convection and replacement of excess UF with sterile replacement fluid


### CVVH

- Fluid removal
- Fluid replacement
- Solute clearance
- Convection
- Minor degree diffusion



### CVVHDF

- Fluid removal
- Solute removal (small and larger solutes)
- Diffusion
- Convection



### Acute renal failure

- RRT?
  - Yes
    - Anuria
    - Metabolic acidosis
    - Fluid management
- IHD or CRRT?
  - CRRT
    - Hemodynamic instability
    - Vasopressor dependency
- Mode?
  - CVVH

### Acute renal failure

- RRT?
  - Yes
    - Anuria
    - Metabolic acidosis
    - Fluid management
- IHD or CRRT?
  - CRRT
    - Hemodynamic instability
    - Vasopressor dependency
- Mode?
  - CVVH
- Dose?

ARTICLE 33


Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial  
Lancet 2000;356:26-30

Claudio Ronco, Rita de Bellomo, Peter Homel, Alessandra Brendolan, Maurizio Dan, Pasquale Piccini, Giuseppe La Greca

### Impact of different haemofiltration doses on outcomes

- 425 patients with ARF
- Randomly assigned ultrafiltration at
  - 20 ml/kg/h
  - 35 ml/kg/h
  - 45 ml/kg/h
- Primary endpoint survival at 15 days after stopping haemofiltration
- Secondary endpoints were recovery of renal function, frequency of complications
- Intention to treat analysis

Ronco et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000;356:26-30.



**Vascular Access**

- **Principles**
  - Vessel(s) and catheters should be large enough to permit blood flow rates > 400 ml/min
  - Venous access preferable to arterial
  - Double lumen catheters preferable
  - Polyurethane preferable to PVC
- **Problems**
  - Poor flow (high positive/negative pressures)
  - Bleeding
  - Clotting
  - Infection
  - Venous stenosis

**Recirculation**

Access recirculation may limit clearances

- Subclavian 4.1%
- Femoral 13.5 cm - 22.8%
- Femoral 19.5 cm - 12.6%
- @Blood flow 300 ml/min

More problematic in IHDF or HVHF than CVVH/CVVHDF

Kelber J et al. *Am J Kidney Dis* 1993; 22: 24-29.  
Leblanc M et al. *J Am Soc Nephrol* 1995; 5: 496.

- What dose CVVH for weight 80 kg?
- Catheter?
  - What type?
  - Where?
  - Why?

**CRRT Treatment, dose and access**

- 24:00 hrs started CVVH
- 3L/hr (37.5 ml/kg/hr)
- Qb 180 ml/hr
- Hemodialysis catheter
  - R. femoral vein 11.5Fr X 19.5 cm
  - PA catheter already in RJJ vein
  - Coagulopathy
  - Preferably avoid subclavian access
    - Risk of pneumothorax in critically ill patient
    - Delayed venous stenosis

**Seminar overview**

- **Part 1**
  - Treatment selection, access and dose
  - Case study
- **Part 2**
  - Fluid balance and electrolyte management
  - Case study

**Fluid and electrolytes 24:00 hrs**

- Septic shock
- Anuric
- Positive 6 liters
- ARDS
- Metabolic (lactic) acidosis
  - pH 7.18, PO2 76, PCO2 45, SaO2 94%, BXS -15
  - Lactate 10 nmol/l
  - Na 138, K 5.6, Cl 102, HCO3 11
  - Urea 19 mmol/l, creatinine 190 µmol/l
- High dose infusions epinephrine and norepinephrine
- Vasopressin and steroid replacement therapy

**Fluid balance during CRRT**

- **Issues**
  - Primary diagnosis
    - Sepsis
    - Trauma
    - Cardiac dysfunction
  - Current status of intravascular fluid volume
  - Ongoing fluid losses
  - Presence of ALI/ARDS
  - Time frame of illness

### ***Fluid balance during CRRT***

- **Issues**
  - **Primary diagnosis**
    - Sepsis
      - Capillary permeability/vasodilatation
      - Vigorous fluid resuscitation
      - Positive fluid balance
    - Cardiac dysfunction
  - **Current status of intravascular fluid volume**
  - **Ongoing fluid losses**
  - **Presence of ALI/ARDS**
  - **Time frame of illness**

### ***Fluid balance during CRRT***

- **Issues**
  - **Primary diagnosis**
    - Sepsis
    - **Cardiac dysfunction**
      - Poor cardiac contractility
      - Cardiogenic pulmonary oedema
      - Negative/even fluid balance
  - **Current status of intravascular fluid volume**
  - **Ongoing fluid losses**
  - **Presence of ALI/ARDS**
  - **Time frame of illness**

### ***Fluid balance during CRRT***

- **Issues**
  - **Primary diagnosis**
    - Sepsis
    - Cardiac dysfunction
  - **Current status of intravascular fluid volume**
    - **If unsure - even or positive fluid balance**
  - **Hemodynamic monitoring**
    - PA catheter
    - PICCO
    - Echocardiography

### ***Fluid balance during CRRT***

- **Issues**
  - **Primary diagnosis**
    - Sepsis
    - Cardiac dysfunction
  - **Current status of intravascular fluid volume**
  - **Ongoing fluid losses**
    - Capillary permeability
    - Burns
    - Bleeding
    - GI losses
  - **Presence of ALI/ARDS**
  - **Time frame of illness**

### ***Fluid balance during CRRT***

- **Issues**
  - **Primary diagnosis**
    - Sepsis
    - Cardiac dysfunction
  - **Current status of intravascular fluid volume**
  - **Ongoing fluid losses**
  - **Presence of ALI/ARDS**
    - Improved survival when fluid overload avoided
  - **Time frame of illness**

### ***Fluid balance during CRRT***

- **Issues**
  - **Primary diagnosis**
    - Sepsis
    - Cardiac dysfunction
  - **Current status of intravascular fluid volume**
  - **Ongoing fluid losses**
  - **Presence of ALI/ARDS**
  - **Time frame of illness**
    - Acute illness – fluid load aggressively
    - Plateau – even balance
    - Recovery- negative fluid balance

### ***Electrolyte management***

- **Issues**
  - Na
  - K
  - HCO<sub>3</sub>
  - Mg
  - PO<sub>4</sub>

### ***Electrolyte management***

- **Issues**
  - Na
    - Generally CRRT fluid - 140 mmol/l
    - Usually limited to available solutions
  - K
  - HCO<sub>3</sub>
  - Mg
  - PO<sub>4</sub>

### **Electrolyte management**

- **Issues**
  - Na
  - K
    - Depends on serum level
    - Generally 3-5 mmol/l
    - Aim to keep serum K level 4-4.5 mmol/l
  - HCO<sub>3</sub>
  - Mg
  - PO<sub>4</sub>

### **Electrolyte management**

- **Issues**
  - Na
  - K
  - HCO<sub>3</sub>
    - Usually fixed 32-35 mmol/l
    - May add extra to CRRT fluid
    - If severe acidosis increase dose ± use IV HCO<sub>3</sub> infusion
  - Mg
  - PO<sub>4</sub>

### **Electrolyte management**

- **Issues**
  - Na
  - K
  - HCO<sub>3</sub>
  - Mg
    - Aim to keep 0.8-1.2 mmol/l, (>1.0 if arrhythmias)
    - Usually fixed 0.5-0.7 mmol/l
    - May require extra MgSO<sub>4</sub> IV 2-4 gms IV over 1-2 hours or continuous infusion
  - PO<sub>4</sub>

### **Electrolyte management**

- **Issues**
  - Na
  - K
  - HCO<sub>3</sub>
  - Mg
  - PO<sub>4</sub>
    - Aim to keep 0.8-1.0 mmol/l
    - Hypophosphataemia relatively common over time with CRRT
    - No phosphate in CRRT fluids
    - May add potassium phosphate or sodium phosphate to calcium free CRRT fluid
    - May supplement PO<sub>4</sub> IV or by NGT as needed

### **Fluid and electrolytes 24:00 hrs**


- Septic shock
- Anuric
- Positive 6 litres
- ARDS
- Metabolic (lactic) acidosis
  - pH 7.18, PO<sub>2</sub> 76, PCO<sub>2</sub> 45, SaO<sub>2</sub> 94%, BXS -15
  - Lactate 10 mmol/l
  - Na 138, K 5.6, Cl 102, HCO<sub>3</sub> 11
  - Urea 19 mmol/l, creatinine 190 µmol/l
- High dose infusions adrenaline and noradrenaline
- Vasopressin and steroid replacement therapy

### **So, what are your CRRT orders, Doctor?.....**

- Fluid management?
  - Positive balance 250 mls/hr
- Electrolyte management
  - CRRT fluid composition
    - Na 140 mmol/l
    - K 4 mmol/l
    - HCO<sub>3</sub> 32 mmol/l
    - Mg 0.5 mmol/l
- Management of acidosis
  - NaHCO<sub>3</sub> infusion 10 mmol/hr IV
  - ABGs with whole blood electrolytes q4h

### **Seminar overview**


- **Part 1**
  - Treatment selection, access and dose
  - Case study
- **Part 2**
  - Fluid balance and electrolyte management
  - Case study
- **Part 3**
  - Monitoring and modification of anticoagulation
  - Case study
- **Discussion**



### **Patient coagulation profile 24:00 hrs**

- Platelets 41
- PTT 95
- INR 1.9
- About to start on Activated Protein C infusion

### Coagulation profile in critically ill

- ↓ Thrombosis
    - Thrombocytopenia
    - Decreased platelet adhesion
    - Decreased fibrinogen
  - ↑ Thrombosis
    - Decreased protein C
    - Decreased protein S
    - Decreased Antithrombin III
    - Heparin induced thrombocytopenia
- 

### Impact of filter clotting

- Decrease in dialysis dose
- Wasted nursing time
- Increase in cost


### Anticoagulation options

- No anticoagulation
- Unfractionated heparin
- LMW Heparin
- Citrate
- Prostaglandins - PGI<sub>2</sub>, PGE<sub>1</sub>
- Heparinoid
- r-Hirudin
- Argatroban


### No Anticoagulation

- Short haemofilter life 6-18 hrs
- Significant system down-time in CRRT
- Wasteful of nursing time
- Expensive at \$180 per M100 Prisma haemofilter
- However, useful if severe coagulopathy

### Unfractionated heparin




### Heparin anticoagulation



### Unfractionated heparin

- Aim for PTT 50-60 secs, ACT 160-180
- If bleeding risk PTT 40-50 secs, ACT 140-160
- Risk of bleeding with heparin
  - 2% per day
  - 3.5-10% of deaths
  - 25% of new hemorrhagic episodes
- If bleeding stop UF heparin
- Mean filter life 24 hrs


### LMW Heparin




### LMW Heparin

- Enoxaparin 8-30u/kg bolus
- Enoxaparin 5u/kg/hr infusion
- LMWH eliminated by kidneys
- Accumulates in renal failure
- No antagonist if bleeding occurs
- Bleeding rates similar to UF Heparin
- Monitoring
  - Free factor Xa levels

### Trisodium citrate



### Citrate anticoagulation



### Citrate anticoagulation

- Trisodium citrate 4% or ACD-A
- Citrate chelates calcium in extracorporeal circuit
- No clotting if serum ionized  $Ca^{++}$  is < 0.25 mmol/l
- On return to patient blood has normal serum ionized calcium levels
- Citrate metabolized to  $HCO_3^-$  and  $H_2O$
- Mean filter life 48 hrs

### Calcium replacement

- Progressive depletion of  $Ca_i$  with continuous TSC/ACD infusions
- Risk of serious hypocalcemia
- Avoid with CaCl infusion
  - Must be via CENTRAL LINE
  - Preferably NOT via CRRT circuit
  - 0.75% solution -20 mls CaCl in 250 mls 0.9% NaCl - start at 60 mls/hr
- Titrate to maintain systemic  $Ca_i$  0.95-1.20

### Complications of citrate anticoagulation for CRRT

- Metabolic alkalosis
- Hypernatraemia
- Ionized hypocalcaemia
  - Paraesthesia
  - Arrhythmia


### Citrate accumulation/toxicity

- Progressive ionized hypocalcemia with increasing serum total calcium
- Cardiac arrhythmias
- Avoid by
  - Keeping blood pump speed 125 mls or less
  - Keeping TSC infusion below 250 mls/min
  - Monitoring  $Ca_i$ /Total Ca ratio

### Monitoring

- Circuit serum ionized calcium q 4-8<sup>h</sup>
  - keep 0.2-0.35 mmol/l
- Systemic serum ionized calcium q 8<sup>h</sup>
  - keep 0.95-1.2 mmol/l
- Serum electrolytes, urea, creatinine q 8<sup>h</sup>
- Arterial blood gases q 8<sup>h</sup>
- Serum Total Ca,  $PO_4$ , and Mg q 8-24<sup>h</sup>
- Daily AST, Bilirubin

### Hemofilter life




### What do you want to do about anticoagulation?

- Platelets 41
- PTT 95
- INR 1.9
- About to start on Activated Protein C infusion

- 24:00 hrs commenced on rAPC (Xigris) 24 mcg/kg/hr infusion
- 24:00 hrs Commenced on CVVH - initially no anticoagulation.
- Hemofilter clotted after 4 hours
- CRRT recommenced - mode CVVHDF with trisodium citrate (TSC) anticoagulation
  - Replacement fluid 1.5 l/hr
  - Dialysate fluid 1.5 l/hr
  - Qb 125 mls/min
  - Fluid balance +200 mls/hr
  - Trisodium citrate 4% infused into circuit at 170 mls/hr
  - Calcium chloride 0.75% infusion via central line at 60 mls/hr - monitored and titrated with systemic whole blood ionized calcium levels every 8 hrs
  - Citrate infusion monitored and titrated using circuit whole blood ionized calcium levels every 8 hrs

### Citrate anticoagulation: CVVHDF



Kutsogiannis D.J, Mayers I, Chin WDN, Gibney RTN. *Am J Kidney Dis* 2000; 35:802-811

- Subsequent steady improvement in hemodynamic status, oxygenation, acid base and coagulopathy
- Noradrenaline weaned off 15:00 hrs day 2, Adrenaline progressively reduced
- Learned that drama group colleague had died
- FIO2 0.4, Lactate 3 nmol/l by 16:00 day 2
- Remained anuric and on CVVHDF
- Adrenaline weaned off and extubated day 3
- Ischemic terminal digits 5th toes
- CVVHDF discontinued on day 3 but remained anuric, requiring IHD for 3 weeks
- Transferred to medicine unit day 6

**"I have learned that good HD is like good lovemaking: It should be performed:**

- as often as possible
- as long as possible
- as gently as possible
- with a maximum of safety"



Gluserix, *Nephrol listserv* 1999